Nordic MDS Group
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Individual Molecular MRD Monitoring for MDS Patients After Allo-SCT
- Conditions
- MRDSCTMDS
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2018-01-30
- Lead Sponsor
- Nordic MDS Group
- Target Recruit Count
- 200
- Registration Number
- NCT02872662
- Locations
- 🇩🇰
Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
🇩🇰Department of Hematology, Rigshospitalet Univsersity Hospital, Copenhagen, Denmark
🇳🇴Department of Medcine, Haukeland University Hospital, Bergen, Norway
The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).
- Conditions
- Myelodysplastic SyndromeAcute Myelogenous Leukemia
- Interventions
- First Posted Date
- 2012-03-16
- Last Posted Date
- 2012-03-16
- Lead Sponsor
- Nordic MDS Group
- Target Recruit Count
- 72
- Registration Number
- NCT01556477
- Locations
- 🇸🇪
Lars Möllgård, Stockholm, Sweden
Safety Study of Eltrombopag Combined With Azacitidine to Treat Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2013-05-03
- Lead Sponsor
- Nordic MDS Group
- Target Recruit Count
- 12
- Registration Number
- NCT01481220
- Locations
- 🇸🇪
4 Locations, Uppsala, Stockholm, Göteborg, Umeå, Sweden
Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
- Conditions
- Myelodysplastic SyndromeChronic Myelomonocytic Leukemia
- Interventions
- Drug: Erythropoetin
- First Posted Date
- 2010-01-13
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- Nordic MDS Group
- Target Recruit Count
- 30
- Registration Number
- NCT01048034
- Locations
- 🇩🇰
Department of Hematology, Aalborg University Hospital, Aalborg, Denmark
🇩🇰Department of Hematology, Aarhus Univsersity Hospital, Aarhus, Denmark
🇩🇰Department of Hematology, Rigshospitalet Univsersity Hospital, Copenhagen, Denmark
Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Nordic MDS Group
- Target Recruit Count
- 28
- Registration Number
- NCT00761449
- Locations
- 🇩🇰
Department of Hematology, Aalborg Hospital, Aalborg, Denmark
🇩🇰Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
🇩🇰Department of Hematology, Rigshospitalet, Copenhagen, Denmark